Related Experiment Video
Updated: Aug 2, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Protease inhibitor use among a community sample of people with HIV disease
E G Bing1, A M Kilbourne, R A Brooks
1Department of Psychiatry, Charles R. Drew University of Medicine and Science, Los Angeles, California 90059, USA.
Objectives:
Protease inhibitors have become integral to HIV disease management. This paper examines sociodemographic factors affecting patient use and perceived knowledge of protease inhibitors, and the relationship between protease inhibitor use and perceived health.
Methods:
1034 people with HIV disease from a large AIDS services organization completed a mailed self-administered survey that assessed sociodemographics, protease inhibitor use and perceived knowledge, and perceived change in health status over the previous year. Multiple logistic regression was used to determine sociodemographic factors independently associated with protease inhibitor use and perceived knowledge, and perceived overall health status.
Results:
Two thirds (66%) of correspondents included in the sample were currently taking protease inhibitors and 52% reported being very knowledgeable about these medications. Adjusting for sociodemographic factors, those who were currently not taking protease inhibitors were more likely to be African American, non-English speaking, earning <$9600 U.S. annually, or uninsured. Among protease inhibitor users, those who reported less knowledge about the drugs were more likely to be nonwhite, earning <$9600 U.S. annually, and not college educated. Protease inhibitor use was independently associated with perceived improved overall health and having been college educated.
Conclusions:
Further efforts should be directed toward increasing use and knowledge of protease inhibitors among disadvantaged populations.
Related Concept Videos
Retrovirus Life Cycles
Subviral Agents
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Antiprotozoal Agents

